CLINICAL AND MOLECULAR CHARACTERISTICS OF ARIEL3 PATIENTS WHO DERIVED EXCEPTIONAL BENEFIT FROM RUCAPARIB MAINTENANCE TREATMENT FOR HIGH-GRADE OVARIAN CANCER (HGOC)

1RL Coleman*, 1A Oza, 4LO Lorusso, 6CAaghajanian, 1A Oaknin, 1D Dean, 1N Colombo, 11W Weberpals, 1I Clamp, 5G Scambia, 1LA Leary, 1RH Holloway, 14MAmenedo Gancedo, 19F Gong, 17DO'Malley, 18MLaley, 16GSoble, 25Kwan, 21LEDermann
1University of Texas MD anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, USA; 2US Oncology Research, Research, The Woodlands, USA; 3Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, Canada; 4Foundation IRCCS, Istituto Nazionale dei Tumori, Multicenter Italian Trials In Ovarian Cancer and Gynecologic Malignancies and Gynecologic Oncology Unit, Milan, Italy; 5Fondazione Policlinico Universitario A. Gemelli IRCCS and Scientific Directorate, Gynecologic Oncology Unit, Rome, Italy; 6Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, USA; 7Val d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Gynecologic Oncology Program, Barcelona, Spain; 8St John of God Subiaco Hospital, Department of Oncology, Subiaco, Australia; 9University of Milan-Bicocca and European Institute of Oncology (IEO) IRCCS, Gynecologic Oncology Program, Milan, Italy; 10Ottawa Hospital Research Institute, Division of Gynecologic Oncology, Ottawa, Canada; 11The Christie NHS Foundation Trust and University of Manchester, Department of Medical Oncology, Manchester, UK; 12Gustave Roussy Cancer Center, INSERM U981, and Group of Investigators Nationaux pour l’Etude des Cancers Ovariens (GINECO), Gynecological Unit, Villejuif, France; 13Florida Hospital Cancer Institute, Department of Gynecologic Oncology, Orlando, USA; 14Oncology Center of Galicia, Medical Oncology Department, La Coruña, Spain; 15Auckland City Hospital and University of Auckland, Medical Oncology Department, Auckland, New Zealand; 16Royal Brisbane and Women’s Hospital, Herston, and University of Queensland, Department of Oncology, Cancer Care Services, St Lucia, Australia; 17The Ohio State University, James Cancer Center, Division of Gynecologic Oncology, Columbus, USA; 18Clovis Oncology, Inc, Clinical Development, Boulder, USA; 19Clovis Oncology, Inc, Molecular Diagnostics and Translational Medicine, Boulder, USA; 20UCI Cancer Institute, University College London and UCL Hospitals, Department of Oncology, London, UK
10.1136/ijgc-2021-IGCS.16

Objectives ARIEL3 is a placebo-controlled randomized trial of the PARP inhibitor (PARPi) rucaparib as maintenance treatment in HGOC patients who responded to the latest line of platinum therapy (NCT01968213). Rucaparib improved progression-free survival (PFS) across all predefined subgroups. Here, we present an exploratory analysis of characteristics associated with exceptional benefit from rucaparib.

Methods Patients were randomized 2:1 to rucaparib 600 mg BID or placebo. As of 31 Dec 2019 (data cutoff), 33/375 (9%) and 1/189 (0.5%) patients were still ongoing and receiving rucaparib or placebo. Molecular features (genomic alterations, BRCA1 promoter methylation) and baseline clinical characteristics were compared between patients who derived exceptional benefit (PFS ≥2 yrs), and those with disease progression on first scan (=12 wks; the short-term subgroup) within each treatment arm.

Results Of 564 patients, 79/375 (21%) in the rucaparib arm and 4/189 (2%) in the placebo arm showed exceptional benefit. Within the rucaparib arm, exceptional benefit patients had more favorable clinical prognostic factors at baseline versus the short-term subgroup (Table). Although BRCA mutations were enriched in the rucaparib exceptional benefit subgroup, 33/79 (42%) of these patients were BRCA wild type. Patterns of enrichment varied among other biomarkers. Overall trends were similar in the placebo arm.

Conclusions Exceptional benefit in ARIEL3 was more common in, but not exclusive to, patients with favorable clinical characteristics and known mechanisms of PARPi sensitivity. Our results suggest rucaparib can deliver exceptional benefit to a diverse set of patients with HGOC.

Efficacy and safety of niraparib maintenance treatment in platinum-sensitive recurrent ovarian cancer after shorter or longer chemotherapy: a post hoc subgroup analysis

1Y Gao, 1X Wu, 1Zhu, 1R Yin, 1J Yang, 1J Liu, 1J Wang, 1L Wu, 1Z Liu, 1D Wang, 1G Lou, 1H Yang, 1Q Zhou, 1B Kong, 1F Huang, 1Chen, 1G Li, 1R An, 1T Tan, 1D Dong, 1Peking University Hospital and Institute, Department of Gynecology, Beijing, China; 2Fudan University Shanghai Cancer Center, Department of Gynecologic Oncology, Shanghai, China; 3Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Department of Gynecologic Oncology, Hangzhou, China; 4West China Second University Hospital, Sichuan University, Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children (sichuan University), Ministry of Education, Chengdu, China; 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Gynecologic Oncology, Beijing, China; 6Sun Yat-sen University Cancer Center, Department of Gynecologic Oncology, Guangzhou, China; 7Fudan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Department of Gynecologic Oncology, Changsha, China; 8National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Gynecologic Oncology, Beijing, China; 9The First Hospital of Jilin University, Department of Oncology, Changchun, China; 10Cancer Hospital of China Medical Academy, Liaoning Cancer Hospital and Institute, Department of Gynecology, Shenyang, China; 11Harbin Medical University Cancer Hospital, Department of Gynecology, Harbin, China; 12The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Department of Gynecologic Oncology, Kunming, China; 13Chongqing University Cancer Hospital, Gynecological Oncology Center, Chongqing, China; 14Qilu Hospital of Shandong University, Department of Obstetrics and Gynecology, Jinan, China; 15Hubei Cancer Hospital, Department of Gynecologic Oncology, Wuhan, China; 16Affiliated Cancer Hospital of Guangzhou Medical University, Department of Gynecologic Oncology, Guangzhou, China; 17Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Cancer Center, Wuhan, China; 18The First Affiliated Hospital of Xi’an Jiaotong University, Department of Obstetrics and Gynecology, Xi’an, China; 19Zai Lab (Shanghai) Co, Ltd, Randall Department, Shanghai, China
10.1136/ijgc-2021-IGCS.17

Objectives Traditionally ≥6 cycles of platinum-containing chemotherapy (Pt-chemo) are recommended for platinum-sensitive recurrent ovarian cancer (PSROC). PARP inhibitor maintenance treatment (MT) can be initiated upon clinical complete/partial response (CR/PR) after ≥4 cycles of chemotherapy. Shorter chemotherapy may improve patient experience without compromising efficacy. This study aims to compare the efficacy and safety of niraparib to placebo as MT administered after ≤4 or >4 cycles of Pt-chemo.